Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

European Journal of Clinical Pharmacology

Volumn 70, Issue 1, 2014, Pages 29-35

  Weller, Stephen ^a   Borland, Julie ^a   Chen, Shuguang ^a   Johnson, Mark ^a   Savina, Paul ^a   Wynne, Brian ^a   Wajima, Toshihiro ^b   Peppercorn, Amanda F ^a   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

Dolutegravir; Pharmacokinetics; Protein binding; Renal impairment

Indexed keywords

DOLUTEGRAVIR;

ADULT; ANALYSIS OF COVARIANCE; AREA UNDER THE CURVE; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY;

EID: 84891881368     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1590-9     Document Type: Review

References (22)

1. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S (2013) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381:735-743. doi: 10.1016/S0140-6736(12) 61853-4
2. G Nichols, A Mills, R Grossberg, et al. (2012) Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3. 11th International Congress on Drug Therapy in HIV Infection (HIV11). Glasgow, November 11-15, 2012. Abstract O232.
3. Cahn P, Posniak AL, Mingrone H, et al (2013) Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700-708
4. Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T (2012) The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 61(3):297-301
5. Min S, Song I, Borland J et al (2010) Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 54:254-258
6. Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S, Lalezari J (2011) Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 25(14):1737-45
7. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW (2013) In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 41:353-61
8. Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, Lou Y, Min S, Goljer I, Culp A, Piscitelli SC, Savina PM (2013) Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor, dolutegravir, in humans. Antimicrob Agents Chemother. doi: 10.1128/AAC.00292-13, ePub ahead of print; 13 May 2013
9. Dreisbach AW, Lertora JJL (2003) The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 16(1):45-50 (Pubitemid 37356766)
10. Food and Drug Administration. (2010) Guidance for industry: Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf. Accessed 27 May 2013.
11. TIVICAY (dolutegravir) prescribing information. ViiV Healthcare, Research Triangle Park, NC, August 2013.
12. Pichette V, Leblond F (2003) Drug metabolism in chronic renal failure. Current Drug Metabolism 4:91-103 (Pubitemid 36443190)
13. Sun H, Frassetto L, Benet L (2006) Effects of renal failure on drug transport and metabolism. Pharmacology & Therapeutics 109:1-11 (Pubitemid 41740811)
14. Naud J, Michaud J, Boisvert C, Desbiens K, Leblond F, Mitchell A, Jones C, Bonnardeaux A, Pichette V (2007) Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther 320(3):978-985 (Pubitemid 46294060)
15. Naud J, Michaud J, Leblond F, Lefrancois S, Bonnardeaux A, Pichette V (2008) Effects of chronic renal failure on liver drug transporters. Drug Met Dispos 36:124-128
16. Liponi DF, Winter ME, Tozer TN (1984) Renal function and therapeutic concentrations of phenytoin. Neurology 34(3):395-7 (Pubitemid 14173229)
17. Lefebvre HP, Ferré J-P, Watson DJ A, Brown CA, Serthelon J-P, Laroute V, Concordet D, Toutain P-L (2001) Small bowel motility and colonic transit are altered in dogs with moderate renal failure. Am J Physiol Regul Integr Comp Physiol 281:R230-R238
18. Strida H, Simrén M, Stotzer P-O, Ringström G, Abrahamsson H, Björnsson ES (2003) Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion 67:129-137 (Pubitemid 36829078)
19. Song I, Borland J, Savina P, Chen S, Patel P, Wajima T, Peppercorn A, Piscitelli S. (2012) Pharmacokinetics of dolutegravir in subjects with moderate hepatic impairment. 19th Conference on Retroviruses and Opportunistic Infections. March 5-8, 2012, Seattle, WA, Abstract 608.
20. Food and Drug Administration. (2008) Guidance for industry: Safety testing of drug metabolites. February 2008. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM079266.pdf Accessed 27 May 2013.
21. van Lunzen J, Maggiolo F, Arribas JR et al (2012) Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 12:111-118
22. Song I, Min SS, Borland J, Lou Y, Chen S, Patel P, Ishibashi T, Piscitelli SC (2011) The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol 51(2):237-42